EWING, NJ--(Marketwire - September 10, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with BurnsAdler Pharmaceuticals, Inc. (BurnsAdler), a specialty pharmaceutical company based in North Carolina under which BurnsAdler will act as DOR's distributor of a Named Patient Access Program (NPAP) for orBec® to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in all countries within Central America, South America and the Caribbean ("Latin America").
